Introduction
extensive and mefloquine is not detectable in the CSF. The drug is very slowly eliminated, mainly as a carboxylic acid metabolite, with a half-time of about 1 Falciparum malaria remains one of the world's biggest killers, accounting for about 2.1 million deaths in 1995-month. It is excreted in breast milk [2 ] . Mefloquine is effective against many isolates of about 4% of all global mortality. The data are even more appalling than at first glance since most deaths chloroquine-resistant P. falciparum, and has become the drug of first-choice for uncomplicated malaria in many are of children aged under 5 years. The vast majority of malaria deaths are in Africa, where the really big issue parts of SE Asia. Resistance to mefloquine is wellrecognised and worsening in SE Asia, but is not yet is preventing mortality rates from rising in the setting of global warming, worsening drug-resistance, severe universal. In Africa mefloquine is little used, mainly because of its high cost; the parasites, for the most part, poverty, rising population pressure and 'competing' disease targets, like acute respiratory infection, TB and retain sensitivity. diarrhoeal illnesses.
Inhabitants of developed nations live, for the most part, in non-endemic areas of the world and become exposed only when they choose to travel-for pleasure, Risk5benefit assessment business or war. Most, if not all, antimalarial drugs have been developed with such travellers, mainly All therapeutic drugs have adverse effects: these may be soldiers, in mind [ 1] . One such drug, mefloquine, has dose/concentration-related or idiosyncratic (much less replaced global malaria mortality as a 'medical headline' common, with less relationship to dose and greater risk recently because of the supposedly unacceptable frebecause of their unpredictability). The physician's job, quency of symptomatic toxicity in travellers. As a result, of course, is to balance anticipated benefit against medical practitioners and patients alike are confused possible risks. about the advisability of prescribing or taking mefloFew would dispute that, faced with established P. quine for malaria prevention.
falciparum parasitaemia (especially in non-immune subjects), the risks of the disease massively outweigh risks of drug treatment. It is in the setting of chemoprophylaxis-where the patient is disease-free-that such risk5benefit 'analysis' becomes particularly relevant and, Background very often, quite difficult. P. falciparum can be transmitted in most tropical countries, but the intensity of In its search for prophylactic drugs for US servicemen, which was accelerated by the war in Vietnam, the transmission is highest in sub-Saharan Africa, particularly in west Africa. Most British malaria deaths are Walter Reed Army Institute of Research screened over a quarter of a million compounds between 1963 and 'imported' from Kenya because of its frequency as a holiday destination. African parasites are usually chloro-1976, and mefloquine was one of the more successful products. Its subsequent development to the market quine-resistant but are sensitive to other drugs at the moment. In contrast, the main tourist destinations of was entrusted to Hoffman LaRoche which introduced mefloquine (Lariam) in the mid-1980s for both the SE Asia pose a much lower threat of malaria transmission, but there are exceptions (for detailed advice treatment of uncomplicated malaria and for prophylaxis.
The drug's mode of action against Plasmodium see Bradley & Warhurst [ 3] ): parasites from SE Asia are not only chloroquine-resistant but are often multifalciparum is unknown, but its effects are confined to the pathogenic blood stages of the parasite. Mefloquine drug-resistant. Overall, mefloquine is the drug of choice for travellers is extensively absorbed from the gut, reaching maximum concentrations after about 2 h. It is very lipid-soluble at high risk of acquiring chloroquine-resistant P. falciparum, and gives greater protection than other drugs in and has a large apparent volume of distribution but, even so, partition across the blood5brain barrier is not sub-Saharan Africa. However, because of concerns about teratogenicity during the first trimester [concerns which each dose, but even so steady-state levels are lower than those achieved very rapidly after 'therapeutic' doses. are not backed up by human data (see )] mefloquine is not recommended for use Concentration-related adverse effects would therefore be expected to be less frequent than during therapeutic use. by pregnant women or those women planning pregnancy within 3 months of the drug. This latter recommen-
The current controversy concerns the frequency with which prophylactic mefloquine is associated with sympdation reflects the drug's very slow elimination from the body.
tomatic adverse events-particularly neuropsychiatric ones (including fatigue, headache, dizziness, sleep disturbance, hallucinations, changes in affect and frank psychosis). Some scientific journals and the popular media, have The mefloquine data sheet recently aired concerns about the safety of prophylactic mefloquine, and we are told in one article that: 'Lariam The newly re-written data sheet for mefloquine lists the following as contraindications:
fends off malaria more effectively than any other drug, but growing evidence of disturbing side effects may soon $ Renal insufficiency and severe impairment of liver function. land its manufacturer in court' [8] . Strong stuff. In this article, Thompson [ 8] cites the numbers of spontaneous $ A history of seizure or psychiatric illness. $ Known hypersensitivity.
adverse reaction reports, two case histories (one of them being a case of 'Lariam-induced chronic fatigue syn-$ Co-administration with halofantrine $ Pregnancy-other than in the presence of compelling drome'), impending litigation by 450 previous mefloquine-users and some opinions from medical experts medical reasons. $ Breast-feeding mothers.
(see also Cook [9 ] ). We are also told by Thompson [ 8] that 'when members of the (malaria) advisory committee The data sheet goes on to advise caution under the following circumstances:
were asked whether they would personally take Lariam, they were divided 50550 down the middle'. Were this $ Women planning pregnancy. $ Young children true, it would leave one wondering what proportion of the committee avoids British beef ! It has to be said that $ Patients with cardiac conduction disorders $ Those undertaking tasks requiring fine coordination the data do not support the semi-anecdotal view that symptomatic, non-life-threatening adverse effects are (including airline pilots).
common enough with prophylactic mefloquine to prompt the drug's avoidance in this setting.
In the present issue of the journal (pp. 415-421 ) the reader will see data from a double-blind, randomised, Adverse reactions to mefloquine placebo-controlled trial in which prophylactic doses of mefloquine induced no symptomatic adverse effects at 'Classical' idiosyncratic reactions to mefloquine-often dermatologic and sometimes life-threatening-are all, except self-limiting diarrhoea [ 10] . Furthermore, the report from Davis and colleagues is largely reported during prophylactic mefloquine use [5, 6 ] but do not appear to be particularly common. In this respect in-keeping with previously published findings. I shall summarise three such large studies.
(1 ) Lobel and mefloquine differs from amodiaquine or Fansidar (pyrimethamine-sulphadoxine), where severe idiosyncratic colleagues [11 ] compared long-term mefloquine prophylaxis with other drug regimens, examining efficacy reactions are unacceptably frequent during chemoprophylaxis and neither drug is recommended for prophy-(in sub-Saharan Africa) and tolerability: weekly mefloquine was 94% more effective than chloroquine, 84% lactic use any longer.
In the doses used for treating malaria (15 to more effective than chloroquine plus proguanil and as well tolerated as either of the other two regimens. (2 ) 25 mg kg−1 as a split dose during one day) dose-related adverse effects are quite frequent with mefloquine and Steffen & colleagues [12 ] gave in-flight questionnaires to all subjects returning to Europe from Kenya in 1985 can interfere with therapy. Early vomiting, which is a major problem because of the need for repeat treatment, and 1991, and 145,003 people completed the survey. Prophylactic effectiveness was 91% for mefloquine, 82% occurs in about 7% of patients and is particularly likely with: higher doses, patients aged <6 or >50 years, high for Fansidar, 72% for chloroquine-proguanil and no better than 42% for chloroquine alone. Adverse effects, fever, and high parasitaemia. Anorexia, nausea, dizziness and sleep disorders are also seen more commonly with which were usually mild, were of similar prevalence in all groups: 18.8% with mefloquine, 18.6% with chlorohigher mefloquine doses [ 7] . Convulsions, other transient acute neurological problems and psychosis can all quine, 30.1% with chloroquine-proguanil and 11.7% with Fansidar. (3) Boudreau & colleagues [13] conduccomplicate falciparum malaria and are therefore difficult to attribute to a drug in that setting with certainty.
ted a double-blind comparison of the tolerability of prophylactic doses of mefloquine or chloroquine in 359 Even so, it does seem clear that mefloquine can cause these reactions in a dose-related manner.
servicemen. There was no compromise in function due to dizziness or incoordination in those given mefloquine The adult prophylactic dose of mefloquine is 250 mg (about 3 to 5 mg kg−1) which is one third of the dose and, the authors conclude, 'overall both weekly mefloquine and loading-dose mefloquine were well tolerated'. used for treatment, but on a weekly basis. Because of its slow rate of elimination the drug accumulates with
It should be noted however that sleep disturbance, Mefloquine 413 increased dream activity and 'depressive feelings' were mittee's updated recommendations on chemoprophylaxis are more keenly awaited than usual this year. more frequent in the mefloquine-treated subjects than in those who took chloroquine in this study.
As a final thought, we would do well to remember that our difficulties with Plasmodium falciparum in the What credence, then, should be given to anecdotal statements that doctors have 'had a colossal number of 'developed world' must be kept in perspective. In my opinion the focus of medical attention should remain in people with memory loss, disorientation, panic attacks, psychosis and epileptic fits' [ 8] ? The spontaneous the tropics, where the real problem (controlling malaria) is to be found. reporting of adverse drug reactions, often as letters to learned journals, is a valued part of our surveillance mechanism and there is no doubt that it should continue. However, the logical outcome of such obserReferences vations should be a careful search for the prevalence rate of such reactions, their severity and outcome
